Yes, I made a mistake in my post (I didn’t reread it before I hit send). What I meant to say is that I don’t think we (those outside of the U.S) are aware of the demographics of those that are dying. China isn’t exactly the most open and cooperative country in the world. We can hypothesize that the population is the young, old, and immunocompromised based on historical data from the flu and other viral outbreaks. Obviously CYDY and the Chinese company will want to target the population most affected in order to reduce mortality (like I said before, probably the main endpoint initially) and not give leronlimab to the population that’s least affected.

I’m assuming they’ll also look at reduction in symptoms and duration of the sickness, but that will take a much larger number of patients. This may only occur if leronlimab lowers mortality and they begin to administer it to everyone.

Honestly, the standard is low right now for leronlimab or any drug that’s competing to treat corona virus (just an FYI, Tamiflu really isn’t that special of a drug). If a drug can cut the mortality rate among corona patients by 25%, that would be huge. The question now is how fast can trials get started, what sample size is appropriate to get statistically significant data and who’s going to get to the finish line first? China is big $.